Akero Therapeutics to Announce New Data from NASH Phase 2a BALANCED Study of AKR-001
Conference Call / Webcast Details
The company will host a conference call and webcast with slide presentation at
About Akero Therapeutics
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health of NASH patients. The company's lead product candidate, AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial.
View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-announce-new-data-from-nash-phase-2a-balanced-study-of-akr-001-301085264.html
SOURCE
Media Contact: Carolyn Hawley, Canale Communications, carolyn@canalecomm.com, 619-849-5382; Investor Contact: Christina Tartaglia, Stern Investor Relations, akero@sternir.com, 212-362-1200